SDPA Summer | Live Blog | Product Theater: Customizing Treatments for Moderate to Severe Acne
Sponsored by Galderma Laboratories, LP
Dr. William Kwan began Thursday’s afternoon session of the SDPA’s Annual Summer Dermatology Conference with a discussion of treatments for moderate to severe acne patients. He explained that with such a large population of patients suffering from acne, it behooves us as providers to get good at treating these patients. Acne is a significant condition with no age limit that affects the quality of life of patients. Dr. Kwan, a specialist in ethnic skin, explained that if “we don’t address the pigmentation” patients won’t feel that they are getting better even if their lesion count is significantly decreased.
Dr. Kwan also explained that it is important to work with acne patients even if, as a provider, you don’t agree with the efficacy of a patient’s method of treatment 100% (e.g. dietary changes). Patient preference for products is key as a patient will lose faith in their provider if he/she doesn’t feel that they are being heard. In addition to patient preference, it is essential to consider efficacy, accessibility and cost when choosing the right product for your acne patient. Epiduo Forte is one of the only approved topical regimens for patients with severe acne.
Dr. Kwan discussed the pathophysiology of acne presentation and the current thinking of subclinical inflammation causing scarring. Epiduo Forte is a product that works on both the inflammatory and bacterial components of acne that is dose dependent. Regardless of severity, scarring can occur with acne. Delay in onset of treating acne increases the risk of scarring. When examining the acne patient, it is important to examine and address the chest and back of these patients. Acne scarring can lead a patient to feel less confident and happy with their appearance. Finally, post-inflammatory hyperpigmentation must be considered as part of the treatment plan and Epiduo Forte is one agent that can improve post-inflammatory erythema and hyperpigmentation.
Byline: Sarah Patton, PA-C, MSHS
Posted: June 2, 2017